Aequs board approves ₹650 crore equity infusion
In short
Aequs’ board approved an equity infusion of about ₹650 crore for capacity expansion. The summary says ₹325 crore will be paid upfront when the warrants are allotted, equal to 50% of the issue size.
This could help Aequs add capacity, but the report does not say which units will expand or when the money will be used. It also does not name the backers.
What the reporting says
Aequs’ board approved an equity infusion of about ₹650 crore for capacity expansion, according to publisher-supplied summaries. Of the total issue size, ₹325 crore will be payable upfront on allotment of the warrants, which is 50% of the issue size and twice the regulatory minimum. The reporting does not identify the investor group, timing of expansion, or the specific facilities to be expanded.
Why it matters
Aequs’ board approved an approximately ₹650 crore equity infusion, with ₹325 crore payable upfront on warrant allotment. The publisher summary says the money is for capacity expansion and notes the upfront amount is twice the regulatory minimum. The reporting does not identify the investors, the expansion plan, or the timeline, so the scale of the operational impact is still unclear.